TBIO - חובות לטווח קצר של החברה Telesis Bio

Telesis Bio, Inc. (TBIO) automates nucleic acid synthesis for scientists, securing a steady profit stream through the sale of proprietary reagents for its installed instruments. This chart of the current share price reflects the -0.01 metric. The company is currently optimizing expenses and revising its BioXp system distribution strategy as it strives to achieve full financial stability and profitability.

This indicator measures the total liabilities of Telesis Bio, Inc. (TBIO) with a maturity horizon of up to one year, reflecting the efficiency of liquidity and working capital management. By analyzing short-term debt statistics, an investor can assess the company's ability to fund the development of proprietary DNA synthesis systems under strict FDA oversight, where borrowing trends serve as a marker between strategic expansion and the risk of funding shortages.